Impact BioMedical, INC. Cost of Revenue
Impact BioMedical, INC. (IBO) reported Cost of Revenue of $1.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Cost of Sales
us-gaap:CostOfRevenue · last filed 2026-08-07
- Impact BioMedical, INC. cost of revenue for the quarter ending 2026-06-30 was $1.00K, a 0.00% change year-over-year.
- Impact BioMedical, INC. cost of revenue for the quarter ending 2025-06-30 was $1.00K.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month |
|---|---|---|
| 2026-06-30 | $1.00K 10-Q · filed 2026-08-07 | $1.00K 10-Q · filed 2026-08-07 |
| 2025-06-30 | $1.00K 10-Q · filed 2026-08-07 | $1.00K 10-Q · filed 2026-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |